Factors determining sensitivity and resistance of tumor cells to arsenic trioxide

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Sertel, Serkan ^a,c,d   Tome, Margaret ^b   Briehl, Margaret M ^b   Bauer, Judith ^c   Hock, Kai ^c   Plinkert, Peter K ^a   Efferth, Thomas ^c,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ARSENIC TRIOXIDE; CATALASE; COMPLEMENTARY DNA; CYTOSKELETON PROTEIN; DIHYDRO 1,3,2 DITHIOARSENOL 2 YLMERCAPTO ACETIC ACID; INTEGRIN LINKED KINASE; MESSENGER RNA; POTASSIUM ARSENITE; PROTEIN BCL 2; PROTEIN P53; THIOREDOXIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOTOXIN; ORGANOARSENIC DERIVATIVE; OXIDE; RNA; TUMOR PROTEIN;

ARTICLE; BCRP GENE; BIOINFORMATICS; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; CLUSTER ANALYSIS; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MDR1 GENE; MELANOMA; MRP1 GENE; ONCOGENE; OVARY CANCER; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR CELL; ACTIN FILAMENT; BIOSYNTHESIS; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ACTIN CYTOSKELETON; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; CYTOTOXINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDES; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84861004569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035584     Document Type: Article

References (82)

1. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S, (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903.
2. Klaassen CD, (1996) Heavy metals and heavy-metal antagonists. J.G. Hardman, AG Gilman, and LE Limbird (eds.) Goodman and Gilman's The Pharmacological basis of therapeutics, 1649-1672 New York McGraW-HILL.
3. Haller JS, (1975) Therapeutic mule: the use of arsenic in the nineteenth century materia medica. Pharmacy in History 17: 87-100.
4. Chan PC, Huff J, (1997) Arsenic carcinogenesis in animals and in humans: mechanistic, experimental, and epidemiological evidence. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev C15: 83-122.
5. Knowles PC, Benson AA, (1983) The biogeochemistry of arsenic. Trends Biochem Sci 8: 178-180.
6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860.
8. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, et al. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARa/PML proteins. Blood 88: 1052-1061.
9. Huang XJ, Wiernik PH, Klein RS, Gallagher RE, (1999) Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 16: 58-64.
10. Anderson KC, Boise LH, Louie R, Waxman S, (2002) Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8: 12-25.
11. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, et al. (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1: 851-860.
12. Liu Q, Hilsenbeck S, Gazitt Y, (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087.
13. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, et al. (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96: 1525-1530.
14. Sawyers CL, (2001) Research on resistance to cancer drug Gleevec. Science 294 (5548): 1834.
15. Efferth T, Kaina B, (2004) Microarray-based prediction of cytotoxicity of tumor cells to arsenic trioxide. Cancer Genomics Proteomics 1: 363-370.
16. Efferth T, (2001) The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1: 45-65.
17. Gillet JP, Efferth T, Remacle J, (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237-262.
18. Perkins C, Kim CN, Fang G, Bhalla KN, (2000) Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95: 1014-1022.
19. Chen X, Zhang M, Liu LX, (2009) The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep 22: 73-80.
20. Seo T, Urasaki Y, Takemura H, Ueda T, (2005) Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines. Anticancer Res 25: 991-998.
21. Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, et al. (2008) A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 22: 1853-1863. Erratum in: Leukemia 23: 431.
22. Brown E, Yedjou CG, Tchounwou PB, (2008) Cytotoxicity and oxidative stress in human liver carcinoma cells exposed to arsenic trioxide (HepG(2). Met Ions Biol Med 10: 583-587.
23. Bowling BD, Doudican N, Manga P, Orlow SJ, (2008) Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol 63: 37-43.
24. Laparra JM, Vélez D, Barberá R, Farré R, Montoro R, (2008) As2O3-induced oxidative stress and cycle progression in a human intestinal epithelial cell line (Caco-2). Toxicol In Vitro 22: 444-449.
25. Yeh JY, Cheng LC, Ou BR, Whanger DP, Chang LW, (2002) Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells. Cell Mol Life Sci 59: 1972-1982.
26. Wang X, Kong L, Zhao J, Yang P, (2002) Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer. Zhonghua Zhong Liu Za Zhi 24: 339-343.
27. Han YH, Kim SH, Kim SZ, Park WH, (2008) Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels. J Cell Biochem 104: 862-878.
28. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, et al. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601.
29. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, et al. (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50: 6793-6799.
30. Brügger D, Herbart H, Gekeler V, Seitz G, Liu C, et al. (1999) Functional analysis of P-glycoprotein and multiderug resistance-associated protein-ralated multidrug resistance in AML-blasts. Leuk Res 23: 467-475.
31. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670.
32. Lam M, Dubyak G, Chen L, Nunez G, Miesfeld RL, et al. (1994) Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci USA 91: 6569-6573.
33. Baker A, Payne CM, Briehl MM, Powis G, (1997) Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57: 5162-5167.
34. Tome ME, Baker AF, Powis G, Payne CM, Briehl MM, (2001) Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth. Cancer Res 61: 2766-2773.
35. Tome ME, Briehl MM, (2001) Thymocytes selected for resistance to hydrogen peroxide show altered antioxidant enzyme profiles and resistance to dexamethasone-induced apoptosis. Cell Death Differ 8: 953-961.
36. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, et al. (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118.
37. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, et al. (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382-394.
38. Efferth T, Briehl MM, Tome ME, (2003) Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol 23: 1231-1235.
39. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
40. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, et al. (2008) Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 68: 415-424.
41. Efferth T, Fabry U, Osieka R, (1997) Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11: 1180-1186.
42. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, et al. (1997) Identification of epidermal growth factor receptor and erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505-1515.
43. Leteurtre F, Kohlhagen G, Paull KD, Pommier Y, (1994) Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J Natl Cancer Inst 86: 1239-1244.
44. Efferth T, Gebhart E, Ross DD, Sauerbrey A, (2003) Identification of gene expression profiles predicting tumor cell response to l-alanosine. Biochem Pharmacol 66: 613-621.
45. Efferth T, Olbrich A, Bauer R, (2002) mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 64: 617-623.
46. Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, et al. (2004) Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 12: 573-580.
47. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, et al. (2005) Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A 102: 7653-7658.
48. Zhao S, Zhang J, Zhang X, Dong X, Sun X, (2008) Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep 35: 421-429.
49. Burnichon V, Jean S, Bellon L, Maraninchi M, Bideau C, et al. (2003) Patterns of gene expressions induced by arsenic trioxide in cultured human fibroblasts. Toxicol Lett 143: 155-162.
50. Wang HY, Liu SX, Zhang M, (2003) Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin 24: 646-650.
51. Liu Q, Zhang H, Smeester L, Zou F, Kesic M, et al. (2010) The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3: 37.
52. Bourdonnay E, Morzadec C, Sparfel L, Galibert MD, Jouneau S, et al. (2009) Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol 46: 649-656.
53. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, et al. (2002) Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 21: 57-63.
54. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, et al. (2002) Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70: 2253-2269.
55. Biswas S, Zhao X, Mone AP, Mo X, Vargo M, et al. (2010) Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res 34: 925-931.
56. Han YH, Kim SZ, Kim SH, Park WH, (2008) Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine. Mol Cells 26: 18-25.
57. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI, (2002) Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8: 566-572.
58. Yang CH, Kuo ML, Chen JC, Chen YC, (1999) Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81: 796-799.
59. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S, (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111.
60. Allen T, Rana SV, (2004) Effect of arsenic (AsIII) on glutathione-dependent enzymes in liver and kidney of the freshwater fish Channa punctatus. Biol Trace Elem Res 100: 39-48.
61. Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, et al. (2006) Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin 27: 1078-1084.
62. Coe E, Schimmer AD, (2008) Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma 49: 1976-1981.
63. Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, et al. (2009) Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid. Free Radic Biol Med 46: 1516-1526.
64. Lu J, Chew EH, Holmgren A, (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104: 12288-12293.
65. Tonissen KF, Di Trapani G, (2009) Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 53: 87-103.
66. Han B, Zhou G, Zhang Q, Zhang J, Wang X, et al. (2004) Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol 4: 335-342.
67. Xue DB, Zhang WH, Yun XG, Song C, Zheng B, et al. (2007) Regulating effects of arsenic trioxide on cell death pathways and inflammatory reactions of pancreatic acinar cells in rats. Chin Med J (Engl) 120: 690-695.
68. Lee C, Lin Y, Huang M, Liu C, Chow J, et al. (2006) Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promyelocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo. Leukemia Lymphoma 47: 521-529.
69. Chan JY, Siu KP, Fung KP, (2006) Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells. Cancer Lett 236: 250-258.
70. Wei H, Su H, Bai D, Zhao H, Ge J, et al. (2003) Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl) 116: 1644-1648.
71. Lehmann S, Bengtzen S, Paul A, Christensson B, Paul C, (2001) Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 66: 357-364.
72. Salerno M, Petroutsa M, Garnier-Suillerot A, (2002) The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation. J Bioenerg Biomembr 34: 135-145.
73. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A, et al. (2001) Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 61: 1387-1391.
74. Seo T, Urasaki Y, Ueda T, (2007) Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance. Int J Hematol 85: 26-31.
75. Au WY, Chim CS, Wai Lie AK, Pang A, Kwong YL, (2002) Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide. Haematologica. 87: 1109-1111.
76. Takeshita A, Shinjo K, Naito K, Matsui H, Shigeno K, et al. (2003) P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As2O3), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells. Leukemia 17: 648-650.
77. Wang DH, Wei HL, Zhao HS, Hao CY, Min ZH, et al. (2005) Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway. Pharmacol Res 52: 376-385.
78. Wang T, Ma LM, Zhang HP, Wang HW, Yang LH, et al. (2007) The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms. Zhonghua Xue Ye Xue Za Zhi 28 438-443. [Article in Chinese].
79. Liang H, Zhang Y, Zhang JD, Gu J, Ma L, et al. (2007) Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02. Zhong Xi Yi Jie He Xue Bao 5 647-650. [Article in Chinese].
80. Xue YW, Han JG, Li BX, Yang BF, (2007) [Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901] Yao Xue Xue Bao 42: 949-953. [Article in Chinese].
81. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, et al. (2002) Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28: 160-168.
82. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, et al. (2004) Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64: 8987-8993.